{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:03:00Z","timestamp":1789419780405,"version":"build-2803163510"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100017700","name":"Henan Provincial Science and Technology Research Project","doi-asserted-by":"publisher","award":["245101610009"],"award-info":[{"award-number":["245101610009"]}],"id":[{"id":"10.13039\/501100017700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017700","name":"Henan Provincial Science and Technology Research Project","doi-asserted-by":"publisher","award":["245101610002"],"award-info":[{"award-number":["245101610002"]}],"id":[{"id":"10.13039\/501100017700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006407","name":"Henan Province Natural Science Foundation","doi-asserted-by":"publisher","award":["232300421117"],"award-info":[{"award-number":["232300421117"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.intimp.2026.117193","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T09:56:09Z","timestamp":1785318969000},"page":"117193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["CircRNA-based CD19-targeted CAR-NK therapy for B-cell acute lymphoblastic Leukemia using a Coccidioides immitis-derived group II intron platform"],"prefix":"10.1016","volume":"187","author":[{"given":"Qisheng","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengbo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoutao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.117193_bb0005","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11684-020-0821-6","article-title":"Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia","volume":"15","author":"Li","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.intimp.2026.117193_bb0010","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","article-title":"Acute lymphoblastic leukaemia","volume":"395","author":"Malard","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2026.117193_bb0015","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41419-023-06019-0","article-title":"Histone acetylation by HBO1 (KAT7) activates Wnt\/\u03b2-catenin signaling to promote leukemogenesis in B-cell acute lymphoblastic leukemia","volume":"14","author":"Wang","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2026.117193_bb0020","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00018-017-2620-z","article-title":"Molecular processes involved in B cell acute lymphoblastic leukaemia","volume":"75","author":"Malouf","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.intimp.2026.117193_bb0025","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41572-024-00525-x","article-title":"Acute lymphoblastic leukaemia","volume":"10","author":"Pagliaro","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.intimp.2026.117193_bb0030","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s40265-019-01120-1","article-title":"Pegaspargase: a review in acute lymphoblastic leukaemia","volume":"79","author":"Heo","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.intimp.2026.117193_bb0035","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.117193_bb0040","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1182\/blood.2023023502","article-title":"Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia","volume":"143","author":"Chalandon","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.117193_bb0045","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1200\/JCO.2017.76.7228","article-title":"Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia: results of Children\u2019s Oncology Group Trial AALL0622","volume":"36","author":"Slayton","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.117193_bb0050","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of Cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"10.1016\/j.intimp.2026.117193_bb0055","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","article-title":"Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons","volume":"20","author":"Naimi","year":"2022","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.intimp.2026.117193_bb0060","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/ajh.26324","article-title":"The clinical outcomes and genomic landscapes of acute lymphoblastic leukemia patients with E2A-PBX1: a 10-year retrospective study","volume":"96","author":"Zhou","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.intimp.2026.117193_bb0065","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13045-023-01482-w","article-title":"Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies, J. Hematol. Oncol","volume":"16","author":"Tapia-Galisteo","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2026.117193_bb0070","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2026.117193_bb0075","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2026.117193_bb0080","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2026.117193_bb0085","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2026.117193_bb0090","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.intimp.2026.117193_bb0095","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2026.117193_bb0100","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2026.117193_bb0105","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/asheducation-2016.1.567","article-title":"Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia","volume":"2016","author":"Frey","year":"2016","journal-title":"Hematology"},{"key":"10.1016\/j.intimp.2026.117193_bb0110","doi-asserted-by":"crossref","first-page":"18729","DOI":"10.1038\/s41598-019-55239-y","article-title":"Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells","volume":"9","author":"Herrera","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2026.117193_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115123","article-title":"IPSC-derived CAR-NK cells for cancer immunotherapy","volume":"165","author":"Lin","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2026.117193_bb0120","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.omtm.2020.06.014","article-title":"Superior expansion and cytotoxicity of human primary NK and CAR-NK cells from various sources via enriched metabolic pathways","volume":"18","author":"Yang","year":"2020","journal-title":"Mol. Ther. - Methods Clin. Dev."},{"key":"10.1016\/j.intimp.2026.117193_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: a promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"eBioMedicine"},{"key":"10.1016\/j.intimp.2026.117193_bb0130","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-021-01083-5","article-title":"Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy, J. Hematol. Oncol","volume":"14","author":"Gong","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2026.117193_bb0135","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.intimp.2026.117193_bb0140","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.stem.2018.07.007","article-title":"Off-the-shelf CAR-NK cells for Cancer immunotherapy","volume":"23","author":"Siegler","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.intimp.2026.117193_bb0145","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.canlet.2019.11.033","article-title":"CAR-NK for tumor immunotherapy: clinical transformation and future prospects","volume":"472","author":"Wang","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2026.117193_bb0150","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2026.117193_bb0155","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.ymthe.2019.03.011","article-title":"Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal Cancer patients","volume":"27","author":"Xiao","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.intimp.2026.117193_bb0160","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41417-021-00365-x","article-title":"CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model","volume":"29","author":"Ng","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.intimp.2026.117193_bb0165","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkae1167","article-title":"Translation of circular RNAs","volume":"53","author":"Margvelani","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.intimp.2026.117193_bb0170","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41587-022-01393-0","article-title":"Engineering circular RNA for enhanced protein production","volume":"41","author":"Chen","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.intimp.2026.117193_bb0175","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/j.cell.2022.04.021","article-title":"Circular RNAs: characterization, cellular roles, and applications","volume":"185","author":"Liu","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2026.117193_bb0180","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1080\/15476286.2016.1239009","article-title":"In vitro circularization of RNA","volume":"14","author":"M\u00fcller","year":"2017","journal-title":"RNA Biol."},{"key":"10.1016\/j.intimp.2026.117193_bb0185","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.omtn.2021.01.003","article-title":"Engineering highly efficient backsplicing and translation of synthetic circRNAs","volume":"23","author":"Meganck","year":"2021","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"10.1016\/j.intimp.2026.117193_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2021.787881","article-title":"Circular RNA: biosynthesis in vitro","volume":"9","author":"Chen","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.intimp.2026.117193_bb0195","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ymeth.2021.02.020","article-title":"The design and synthesis of circular RNAs","volume":"196","author":"Obi","year":"2021","journal-title":"Methods"},{"key":"10.1016\/j.intimp.2026.117193_bb0200","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.omtn.2023.07.034","article-title":"Efficient circular RNA engineering by end-to-end self-targeting and splicing reaction using Tetrahymena group I intron ribozyme","volume":"33","author":"Lee","year":"2023","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"10.1016\/j.intimp.2026.117193_bb0205","doi-asserted-by":"crossref","DOI":"10.1002\/wrna.1466","article-title":"Therapeutic applications of group I intron-based trans -splicing ribozymes","volume":"9","author":"Lee","year":"2018","journal-title":"WIREs RNA"},{"key":"10.1016\/j.intimp.2026.117193_bb0210","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a032375","article-title":"Group II intron RNPs and reverse Transcriptases: from retroelements to research tools","volume":"11","author":"Belfort","year":"2019","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.intimp.2026.117193_bb0215","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1038\/s41467-018-05096-6","article-title":"Engineering circular RNA for potent and stable translation in eukaryotic cells","volume":"9","author":"Wesselhoeft","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2026.117193_bb0220","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.cell.2022.03.044","article-title":"Circular RNA vaccines against SARS-CoV-2 and emerging variants","volume":"185","author":"Qu","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2026.117193_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102258","article-title":"Circular RNA-based therapy provides sustained and robust neuroprotection for retinal ganglion cells","volume":"35","author":"Jiang","year":"2024","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"10.1016\/j.intimp.2026.117193_bb0230","doi-asserted-by":"crossref","first-page":"6422","DOI":"10.7150\/thno.77350","article-title":"Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies","volume":"12","author":"Li","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.intimp.2026.117193_bb0235","article-title":"Enhanced antitumor efficacy of STING agonist MSA-2 by lipid nanoparticles delivering circular IL-23 mRNA and platinum-modified MSA-2 combination","volume":"30","author":"He","year":"2025","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.intimp.2026.117193_bb0240","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40164-025-00625-8","article-title":"Engineered circular RNA-based DLL3-targeted CAR-T therapy for small cell lung cancer","volume":"14","author":"Cai","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2026.117193_bb0245","article-title":"Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in vivo CAR-T therapy for inflamm-aging","volume":"6","author":"Zhang","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.intimp.2026.117193_bb0250","article-title":"A flexible, efficient, and scalable platform to produce circular RNAs as new therapeutics","author":"Wei","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.intimp.2026.117193_bb0255","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.ymthe.2024.04.028","article-title":"Circular RNA vaccines against monkeypox virus provide potent protection against vaccinia virus infection in mice","volume":"32","author":"Zhou","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.intimp.2026.117193_bb0260","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41551-024-01245-z","article-title":"Robust genome and cell engineering via in vitro and in situ circularized RNAs","volume":"9","author":"Tong","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.intimp.2026.117193_bb0265","doi-asserted-by":"crossref","first-page":"7376","DOI":"10.1038\/s41467-025-62607-y","article-title":"Self-splicing RNA circularization facilitated by intact group I and II introns","volume":"16","author":"Shen","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2026.117193_bb0270","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.3390\/ijms24044197","article-title":"4-1BB-based CAR T cells effectively reverse exhaustion and enhance the anti-tumor immune response through autocrine PD-L1 scFv antibody","volume":"24","author":"Cheng","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.117193_bb0275","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/bloodadvances.2023012202","article-title":"CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy","volume":"8","author":"Guo","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.intimp.2026.117193_bb0280","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1007\/s00262-023-03422-6","article-title":"Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia","volume":"72","author":"Cheng","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2026.117193_bb0285","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.117193_bb0290","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.intimp.2026.117193_bb0295","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70140","article-title":"Enhancement of anti-sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2-targeted CAR","volume":"15","author":"Lam","year":"2025","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.intimp.2026.117193_bb0300","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.tibtech.2023.08.005","article-title":"Chimeric antigen receptor therapy meets mRNA technology","volume":"42","author":"Wu","year":"2024","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.intimp.2026.117193_bb0305","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","article-title":"The clinical progress of mRNA vaccines and immunotherapies","volume":"40","author":"Barbier","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.intimp.2026.117193_bb0310","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.intimp.2026.117193_bb0315","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12967-022-03326-6","article-title":"Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells","volume":"20","author":"Roex","year":"2022","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.intimp.2026.117193_bb0320","doi-asserted-by":"crossref","first-page":"5944","DOI":"10.1021\/acs.molpharmaceut.4c00826","article-title":"Development of thermally stable mRNA-LNP delivery systems: current Progress and future prospects","volume":"21","author":"Kafle","year":"2024","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.intimp.2026.117193_bb0325","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.3390\/v15081697","article-title":"Functional involvement of circRNAs in the innate immune responses to viral infection","volume":"15","author":"Maarouf","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.intimp.2026.117193_bb0330","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41392-025-02512-4","article-title":"Scarless circular mRNA-based CAR-T cell therapy elicits superior antitumor efficacy","volume":"10","author":"Hu","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2026.117193_bb0335","article-title":"Synergically enhanced anti-tumor immunity of in vivo panCAR by circRNA vaccine boosting","volume":"6","author":"Wang","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.intimp.2026.117193_bb0340","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.omto.2021.10.001","article-title":"The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy","volume":"23","author":"Fabian","year":"2021","journal-title":"Mol. Ther. - Oncolytics"},{"key":"10.1016\/j.intimp.2026.117193_bb0345","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00262-015-1761-x","article-title":"NK-92: an \u2018off-the-shelf therapeutic\u2019 for adoptive natural killer cell-based cancer immunotherapy","volume":"65","author":"Suck","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2026.117193_bb0350","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.intimp.2026.117193_bb0355","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1274","article-title":"CAR-NK cells: the next wave of cellular therapy for cancer","volume":"10","author":"Daher","year":"2021","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.intimp.2026.117193_bb0360","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s13046-025-03558-6","article-title":"Challenges and opportunities of human iPSC-derived NK as \u201coff-the-shelf\u201d cellular therapies","volume":"44","author":"Romanini","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.117193_bb0365","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004693","article-title":"Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells","volume":"10","author":"Maddineni","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2026.117193_bb0370","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00091","article-title":"Natural killer cells for immunotherapy \u2013 advantages of the NK-92 cell line over blood NK cells","volume":"7","author":"Klingemann","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117193_bb0375","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000450","article-title":"PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations","volume":"8","author":"Fabian","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2026.117193_bb0380","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/ijc.30767","article-title":"ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody: haNK expressing the high affinity CD16 allele with avelumab","volume":"141","author":"Jochems","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.intimp.2026.117193_bb0385","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3389\/fimmu.2017.00533","article-title":"Chimeric antigen receptor-engineered NK-92 cells: an off-the-shelf cellular therapeutic for targeted elimination of Cancer cells and induction of protective antitumor immunity","volume":"8","author":"Zhang","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117193_bb0390","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1692107","article-title":"Construction of anti-HER2 affibody-directed CAR-NK and its synergistic effects with doxorubicin-loaded nanodrug against HER2-positive breast cancer","volume":"16","author":"He","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117193_bb0395","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12967-022-03326-6","article-title":"Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells","volume":"20","author":"Roex","year":"2022","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.intimp.2026.117193_bb0400","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1186\/s12967-025-06753-3","article-title":"Robo1 CAR-NK92 and radiotherapy exert synergistic efficacy in solid tumors","volume":"23","author":"Wu","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.intimp.2026.117193_bb0405","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbaf263","article-title":"Artificial intelligence-driven circRNA vaccine development: multimodal collaborative optimization and a new paradigm for biomedical applications","volume":"26","author":"Zhao","year":"2025","journal-title":"Brief. Bioinform."},{"key":"10.1016\/j.intimp.2026.117193_bb0410","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.molcel.2019.02.015","article-title":"RNA circularization diminishes immunogenicity and can extend translation duration in vivo","volume":"74","author":"Wesselhoeft","year":"2019","journal-title":"Mol. Cell"}],"updated-by":[{"DOI":"10.1016\/j.intimp.2026.117285","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000}},{"DOI":"10.1016\/j.intimp.2026.117285","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000}}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926010398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926010398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T20:09:08Z","timestamp":1789416548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926010398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":82,"alternative-id":["S1567576926010398"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117193","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CircRNA-based CD19-targeted CAR-NK therapy for B-cell acute lymphoblastic Leukemia using a Coccidioides immitis-derived group II intron platform","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117193","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117193"}}